$20.6 Billion is the total value of Baker Brothers Advisors's 121 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 9.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Sell | Seagen Inc. | $7,249,714 | -9.7% | 46,893,364 | -0.8% | 35.27% | +0.0% |
| BGNE | BeiGene, Ltd.sponsored adr | $3,161,454 | -25.4% | 11,668,897 | 0.0% | 15.38% | -17.3% | |
| INCY | Buy | Incyte Corporation | $2,467,566 | +12.0% | 33,618,063 | +5.0% | 12.01% | +24.1% |
| KOD | Kodiak Sciences Inc. | $1,244,681 | -11.7% | 14,681,304 | 0.0% | 6.06% | -2.1% | |
| ACAD | ACADIA Pharmaceuticals Inc. | $978,196 | +40.5% | 41,910,704 | 0.0% | 4.76% | +55.7% | |
| BMRN | BioMarin Pharmaceutical Inc. | $673,271 | +14.3% | 7,620,494 | 0.0% | 3.28% | +26.7% | |
| ASND | Ascendis Pharma A/Ssponsored adr | $610,982 | -15.6% | 4,541,604 | 0.0% | 2.97% | -6.5% | |
| ARGX | argenx SEsponsored adr | $392,058 | +16.0% | 1,119,557 | 0.0% | 1.91% | +28.4% | |
| MRTX | Mirati Therapeutics, Inc. | $206,801 | -17.1% | 1,409,784 | 0.0% | 1.01% | -8.1% | |
| BCRX | BioCryst Pharmaceuticals, Inc. | $176,045 | -3.6% | 12,710,818 | 0.0% | 0.86% | +6.9% | |
| KYMR | Kymera Therapeutics, Inc. | $151,407 | +8.1% | 2,384,742 | 0.0% | 0.74% | +19.8% | |
| NVTA | Invitae Corporation | $150,768 | -46.3% | 9,873,488 | 0.0% | 0.73% | -40.5% | |
| ABCL | AbCellera Biologics Inc. | $149,438 | -28.6% | 10,450,180 | 0.0% | 0.73% | -21.0% | |
| MDGL | Madrigal Pharmaceuticals, Inc. | $127,043 | +6.2% | 1,499,213 | 0.0% | 0.62% | +17.7% | |
| PRLD | Prelude Therapeutics Inc. | $126,042 | -60.2% | 10,123,824 | 0.0% | 0.61% | -55.9% | |
| LEGN | Buy | Legend Biotech Corporationsponsored ads | $116,012 | -2.9% | 2,489,003 | +5.3% | 0.56% | +7.4% |
| PACB | Pacific Biosciences of California, Inc. | $111,404 | -19.9% | 5,444,963 | 0.0% | 0.54% | -11.3% | |
| GBT | Buy | Global Blood Therapeutics, Inc. | $97,023 | +18.3% | 3,314,765 | +3.0% | 0.47% | +31.1% |
| CERS | Cerus Corporation | $93,387 | +11.8% | 13,713,195 | 0.0% | 0.45% | +23.7% | |
| IGMS | IGM Biosciences, Inc. | $92,568 | -55.4% | 3,156,102 | 0.0% | 0.45% | -50.6% | |
| IMCR | Immunocore Holdings plcads | $86,310 | -7.6% | 2,520,730 | 0.0% | 0.42% | +2.4% | |
| TVTX | Buy | Travere Therapeutics, Inc. | $82,847 | +67.5% | 2,669,054 | +30.9% | 0.40% | +85.7% |
| New | Entrada Therapeutics, Inc. | $80,540 | – | 4,704,419 | +100.0% | 0.39% | – | |
| HRTX | Heron Therapeutics, Inc. | $74,242 | -14.6% | 8,131,678 | 0.0% | 0.36% | -5.5% | |
| AMRN | Sell | Amarin Corporation plcsponsored adr | $71,342 | -36.0% | 21,169,805 | -3.1% | 0.35% | -29.0% |
| NRIX | Nurix Therapeutics, Inc. | $71,046 | -3.4% | 2,454,082 | 0.0% | 0.35% | +7.1% | |
| TIL | Instil Bio, Inc. | $66,621 | -4.3% | 3,893,700 | 0.0% | 0.32% | +5.9% | |
| MRUS | Merus N.V. | $64,792 | +44.5% | 2,037,469 | 0.0% | 0.32% | +59.9% | |
| HZNP | Horizon Therapeutics Public Ltd Co | $64,560 | -1.6% | 599,110 | 0.0% | 0.31% | +9.0% | |
| CCXI | Buy | ChemoCentryx, Inc. | $59,394 | +1053.3% | 1,631,266 | +441.6% | 0.29% | +1156.5% |
| IMTX | Immatics N.V. | $59,455 | +3.4% | 4,423,731 | 0.0% | 0.29% | +14.2% | |
| INSM | Insmed Incorporated | $58,729 | -1.1% | 2,156,001 | 0.0% | 0.29% | +9.6% | |
| NBIX | Neurocrine Biosciences, Inc. | $57,658 | -11.2% | 676,975 | 0.0% | 0.28% | -1.4% | |
| KRYS | Buy | Krystal Biotech, Inc. | $56,501 | +78.1% | 807,735 | +32.9% | 0.28% | +97.8% |
| VERV | Verve Therapeutics, Inc. | $52,227 | -21.6% | 1,416,530 | 0.0% | 0.25% | -13.0% | |
| Sell | Apellis Pharmaceuticals, Inc.note 3.5% 9/15/2026 | $47,968 | -16.2% | 31,754,000 | -32.1% | 0.23% | -7.2% | |
| VSTM | Verastem, Inc. | $44,058 | -33.4% | 21,491,630 | 0.0% | 0.21% | -26.5% | |
| Insmed Incorporatednote 0.75% 6/1/2028 | $43,336 | -1.1% | 40,000,000 | 0.0% | 0.21% | +9.3% | ||
| Sarepta Therapeutics, Inc.dbcv 1.5% 11/15/2024 | $42,695 | -1.1% | 29,174,000 | 0.0% | 0.21% | +9.5% | ||
| RYTM | Rhythm Pharmaceuticals, Inc. | $38,555 | -23.6% | 3,863,239 | 0.0% | 0.19% | -15.3% | |
| KDNY | Buy | Chinook Therapeutics, Inc. | $38,069 | +56.8% | 2,334,102 | +22.6% | 0.18% | +72.9% |
| RARE | Ultragenyx Pharmaceutical Inc. | $37,373 | -6.8% | 444,444 | 0.0% | 0.18% | +3.4% | |
| ADAP | Adaptimmune Therapeutics plcsponsored adr | $36,866 | -27.5% | 9,830,877 | 0.0% | 0.18% | -19.7% | |
| ALKS | Buy | Alkermes plc | $34,890 | -7.9% | 1,500,000 | +22.1% | 0.17% | +2.4% |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $32,951 | +3.3% | 2,799,577 | 0.0% | 0.16% | +14.3% | |
| DSGN | Design Therapeutics, Inc. | $30,758 | +45.7% | 1,436,636 | 0.0% | 0.15% | +61.3% | |
| TLIS | Buy | Talis Biomedical Corporation | $30,576 | -35.4% | 7,624,835 | +0.7% | 0.15% | -28.4% |
| FMTX | Forma Therapeutics Holdings, Inc. | $28,794 | -38.7% | 2,024,876 | 0.0% | 0.14% | -32.0% | |
| ZYME | Zymeworks Inc. | $28,002 | -43.6% | 1,708,472 | 0.0% | 0.14% | -37.6% | |
| BLUE | bluebird bio, Inc. | $24,972 | -47.7% | 2,499,715 | 0.0% | 0.12% | -42.4% | |
| ALGS | Aligos Therapeutics, Inc. | $24,647 | -23.5% | 2,076,400 | 0.0% | 0.12% | -14.9% | |
| OPT | Sell | Opthea Limitedsponsored ads | $24,115 | -10.9% | 3,196,191 | -5.5% | 0.12% | -1.7% |
| CRNX | Sell | Crinetics Pharmaceuticals, Inc. | $23,509 | +21.3% | 827,480 | -10.1% | 0.11% | +34.1% |
| XENE | Xenon Pharmaceuticals Inc. | $23,481 | +104.4% | 751,639 | 0.0% | 0.11% | +128.0% | |
| DBVT | DBV Technologies S.A.sponsored adr | $23,383 | -67.3% | 14,614,264 | 0.0% | 0.11% | -63.7% | |
| AXSM | Buy | Axsome Therapeutics, Inc. | $23,082 | +29.9% | 610,970 | +13.3% | 0.11% | +43.6% |
| AVTE | Buy | Aerovate Therapeutics, Inc. | $21,597 | -37.7% | 1,831,789 | +10.9% | 0.10% | -30.9% |
| New | 2seventy bio, Inc. | $21,356 | – | 833,236 | +100.0% | 0.10% | – | |
| FLGT | Sell | Fulgent Genetics, Inc. | $20,263 | -43.8% | 201,444 | -49.8% | 0.10% | -37.3% |
| NLTX | Neoleukin Therapeutics, Inc. | $18,421 | -33.3% | 3,821,740 | 0.0% | 0.09% | -25.6% | |
| OTIC | Buy | Otonomy, Inc. | $16,317 | +10.5% | 7,844,692 | +2.0% | 0.08% | +21.5% |
| AGLE | Aeglea BioTherapeutics, Inc. | $16,198 | -40.3% | 3,410,106 | 0.0% | 0.08% | -33.6% | |
| BCAB | BioAtla, Inc. | $16,195 | -33.3% | 825,000 | 0.0% | 0.08% | -26.2% | |
| REPL | Buy | Replimune Group, Inc. | $16,081 | +253.4% | 593,395 | +286.5% | 0.08% | +290.0% |
| Surrozen, Inc. | $16,100 | -9.0% | 2,500,000 | 0.0% | 0.08% | 0.0% | ||
| Sell | Tricida, Inc.note 3.5% 5/15/2027 | $14,828 | -52.7% | 27,500,000 | -63.3% | 0.07% | -47.8% | |
| ANAB | AnaptysBio, Inc. | $14,844 | +28.1% | 427,179 | 0.0% | 0.07% | +41.2% | |
| DICE Therapeutics, Inc. | $14,888 | -22.7% | 588,235 | 0.0% | 0.07% | -15.3% | ||
| AFMD | Buy | Affimed N.V. | $14,645 | +1340.0% | 2,653,169 | +1511.8% | 0.07% | +1675.0% |
| ACHL | Achilles Therapeutics plcsponsored ads | $12,983 | -35.7% | 2,591,366 | 0.0% | 0.06% | -29.2% | |
| CNTA | Centessa Pharmaceuticals plcsponsored ads | $12,693 | -32.6% | 1,127,273 | 0.0% | 0.06% | -25.3% | |
| TCDA | Buy | Tricida, Inc. | $12,285 | +155.2% | 1,285,014 | +23.9% | 0.06% | +185.7% |
| SRPT | New | Sarepta Therapeutics, Inc. | $11,117 | – | 123,456 | +100.0% | 0.05% | – |
| RLMD | Buy | Relmada Therapeutics, Inc. | $11,155 | +111.8% | 495,113 | +146.3% | 0.05% | +134.8% |
| BCEL | Atreca, Inc. | $10,704 | -51.4% | 3,532,760 | 0.0% | 0.05% | -46.4% | |
| ATHA | Athira Pharma, Inc. | $10,507 | +38.9% | 806,367 | 0.0% | 0.05% | +54.5% | |
| ALT | Altimmune, Inc. | $9,820 | -19.0% | 1,072,038 | 0.0% | 0.05% | -9.4% | |
| Invitae Corporationnote 2.0% 9/1/2024 | $9,623 | -23.4% | 10,300,000 | 0.0% | 0.05% | -14.5% | ||
| KRTX | Karuna Therapeutics, Inc. | $9,166 | +7.1% | 69,966 | 0.0% | 0.04% | +18.4% | |
| CYT | Cyteir Therapeutics, Inc. | $9,240 | -35.2% | 812,640 | 0.0% | 0.04% | -28.6% | |
| FGEN | New | FibroGen, Inc. | $8,180 | – | 580,150 | +100.0% | 0.04% | – |
| Tango Therapeutics, Inc. | $8,205 | -15.4% | 750,000 | 0.0% | 0.04% | -7.0% | ||
| EWTX | Edgewise Therapeutics, Inc. | $7,640 | -8.0% | 500,000 | 0.0% | 0.04% | +2.8% | |
| CBAY | CymaBay Therapeutics, Inc. | $7,336 | -7.4% | 2,170,464 | 0.0% | 0.04% | +2.9% | |
| MGNX | MacroGenics, Inc. | $7,103 | -23.4% | 442,579 | 0.0% | 0.04% | -14.6% | |
| NVAX | Sell | Novavax, Inc. | $6,891 | -69.4% | 48,168 | -55.7% | 0.03% | -65.7% |
| ITOS | Iteos Therapeutics, Inc. | $7,000 | +72.5% | 150,346 | 0.0% | 0.03% | +88.9% | |
| ALLK | Allakos Inc. | $6,883 | -90.8% | 703,050 | 0.0% | 0.03% | -89.9% | |
| TScan Therapeutics, Inc. | $6,413 | -46.0% | 1,425,000 | 0.0% | 0.03% | -40.4% | ||
| RETA | Reata Pharmaceuticals, Inc.cl a | $5,906 | -73.8% | 223,976 | 0.0% | 0.03% | -70.7% | |
| RVMD | Revolution Medicines, Inc. | $5,593 | -8.5% | 222,222 | 0.0% | 0.03% | 0.0% | |
| HRMY | Harmony Biosciences Holdings, Inc. | $5,270 | +11.2% | 123,600 | 0.0% | 0.03% | +23.8% | |
| NGM | NGM Biopharmaceuticals, Inc. | $5,168 | -15.7% | 291,801 | 0.0% | 0.02% | -7.4% | |
| ALEC | Alector, Inc. | $4,940 | -9.5% | 239,228 | 0.0% | 0.02% | 0.0% | |
| LIFE | aTyr Pharma, Inc. | $4,669 | -17.7% | 625,000 | 0.0% | 0.02% | -8.0% | |
| KURA | Kura Oncology, Inc. | $4,258 | -25.3% | 304,158 | 0.0% | 0.02% | -16.0% | |
| BMEA | Biomea Fusion, Inc. | $3,908 | -37.8% | 524,617 | 0.0% | 0.02% | -32.1% | |
| DNLI | Denali Therapeutics Inc. | $3,958 | -11.6% | 88,738 | 0.0% | 0.02% | -5.0% | |
| TCRR | Buy | TCR2 Therapeutics Inc. | $3,509 | +133.6% | 753,064 | +326.8% | 0.02% | +142.9% |
| GTH | Genetron Holdings Limitedads | $2,777 | -56.0% | 455,306 | 0.0% | 0.01% | -50.0% | |
| ALBO | Sell | Albireo Pharma, Inc. | $2,434 | -81.1% | 104,521 | -74.7% | 0.01% | -78.9% |
| AKRO | Akero Therapeutics, Inc. | $2,504 | -5.4% | 118,378 | 0.0% | 0.01% | 0.0% | |
| SNDX | Syndax Pharmaceuticals, Inc. | $2,424 | +14.6% | 110,729 | 0.0% | 0.01% | +33.3% | |
| VINC | Vincerx Pharma, Inc. | $2,460 | -37.0% | 241,379 | 0.0% | 0.01% | -29.4% | |
| CABA | Cabaletta Bio, Inc. | $2,509 | -68.8% | 662,063 | 0.0% | 0.01% | -65.7% | |
| KZR | Kezar Life Sciences, Inc. | $2,335 | +93.5% | 139,676 | 0.0% | 0.01% | +120.0% | |
| BNR | Burning Rock Biotech Limitedsponsored ads | $1,993 | -46.7% | 209,131 | 0.0% | 0.01% | -37.5% | |
| LPTX | Leap Therapeutics, Inc. | $1,813 | -19.2% | 559,705 | 0.0% | 0.01% | -10.0% | |
| HOOK | HOOKIPA Pharma Inc. | $1,632 | -60.4% | 700,481 | 0.0% | 0.01% | -55.6% | |
| GMDA | Gamida Cell Ltd. | $1,551 | -35.2% | 610,626 | 0.0% | 0.01% | -27.3% | |
| TARA | Protara Therapeutics, Inc. | $1,348 | -2.5% | 199,671 | 0.0% | 0.01% | +16.7% | |
| NEXI | NexImmune, Inc. | $1,356 | -69.5% | 294,117 | 0.0% | 0.01% | -65.0% | |
| Sera Prognostics, Inc. | $1,385 | -38.1% | 201,562 | 0.0% | 0.01% | -30.0% | ||
| FHTX | New | Foghorn Therapeutics Inc. | $1,030 | – | 45,027 | +100.0% | 0.01% | – |
| Surrozen, Inc.w exp 8/11/2026 | $958 | +0.8% | 833,333 | 0.0% | 0.01% | +25.0% | ||
| OYST | Oyster Point Pharma, Inc. | $1,122 | +54.1% | 61,424 | 0.0% | 0.01% | +66.7% | |
| LOGC | LogicBio Therapeutics, Inc. | $1,043 | -49.6% | 451,478 | 0.0% | 0.01% | -44.4% | |
| EVFM | Evofem Biosciences, Inc. | $1,013 | -49.1% | 2,697,110 | 0.0% | 0.01% | -44.4% | |
| INZY | Inozyme Pharma, Inc. | $730 | -41.1% | 106,999 | 0.0% | 0.00% | -20.0% | |
| PASG | Passage Bio, Inc. | $744 | -36.2% | 117,161 | 0.0% | 0.00% | -20.0% | |
| Bellicum Pharmaceuticals, Inc. | $371 | -49.0% | 249,123 | 0.0% | 0.00% | -33.3% | ||
| MREO | Exit | Mereo BioPharma Group plcads | $0 | – | -292,692 | -100.0% | -0.00% | – |
| XLRN | Exit | Acceleron Pharma Inc. | $0 | – | -22,430 | -100.0% | -0.02% | – |
| Exit | BioMarin Pharmaceutical Inc.note 0.599% 8/1/2024 | $0 | – | -4,500,000 | -100.0% | -0.02% | – | |
| AMYT | Exit | Amryt Pharma plcsponsored adr | $0 | – | -518,380 | -100.0% | -0.03% | – |
| AUPH | Exit | Aurinia Pharmaceuticals Inc. | $0 | – | -520,523 | -100.0% | -0.05% | – |
| MIRM | Exit | Mirum Pharmaceuticals, Inc. | $0 | – | -647,313 | -100.0% | -0.06% | – |
Source
Signed by
- Alexandra Toohey — Chief Financial Officer
- Baker Brothers Advisors holdings (13F-HR)
- Baker Brothers Advisors significant holdings (13D/G)
- Baker Brothers Advisors ownership history
- Baker Brothers Advisors portfolio value
- Baker Brothers Advisors insiders transactions
- Baker Brothers Advisors filings
- Similar filers BETA
Compare quarterly holdings
Export Baker Brothers Advisors's holdings